ChromaDex Corp. (Los Angeles, CA) has announced the expansion of its industry-leading reference standards business with a new line of cannabinoid (CBD) reference standards available to researchers across the globe. These new materials are for laboratory use only, not for human consumption.
“In the CBD space, we see an abundance of misinformation and a dearth of quality standards testing,” said Rob Fried, ChromaDex CEO and member of the Board of Directors of the Council for Responsible Nutrition (CRN). “ChromaDex has been a leader in standards testing for over 20 years, and we look forward to helping bring some scientific integrity to those interested in CBD.”
Reference standards are used as benchmarks or markers to confirm the identity and potency of products. ChromaDex is a leading provider of phytochemical reference standards, botanical reference materials, and research grade materials for the natural products industry with more than 1,750 phytochemicals and 400 botanical reference materials in its catalog.
The company welcomes two cannabinoid reference standards, Cannabidiol (CBD) and Cannabidivarin (CBD-V), derived from hemp for laboratory use in the identification and qualification of hemp and CBD ingredients or products.
“We support the establishment of a safe limit of CBD for consumers,” noted ChromaDex Co-Founder & Executive Chairman Frank Jaksch. “Our tools will help researchers and companies develop quality products that match label claims.”
For more information, visit https://standards.chromadex.com.
